Harvard, Late Night Eating Impact, New study provides experimental evidence that late eating may increase hunger, obesity risk
Obesity afflicts approximately 42 percent of the U. S. adult population and contributes to the onset of chronic diseases, including diabetes, cancer, and other conditions, mehr …
xn--gtsel-kva.de/content/51864/harvard-late-night-eating-impact-new-study-provides-experimental-evidence-that-late-eating-may-increase-hunger-obesity-risk.html
Financial report for the period 1 January 2021 to 31 December 2021
Operating profit increased by 8% in Danish kroner and by 13% at constant exchange rates (CER) to DKK 58.6 billion, mehr …
xn--gtsel-kva.de/content/36087/financial-report-for-the-period-1-january-2021-to-31-december-2021.html
Das britische Lebensmittelumfeld untergräbt aktiv die Bemühungen der Menschen, abzunehmen und ihr Gewicht zu halten
Eine neue systematische Untersuchung der NIHR Obesity Policy Research Unit gibt der britischen Regierung wichtige politische Empfehlungen zur Eindämmung der Fettleibigkeitskrise, mehr …
xn--gtsel-kva.de/content/34077/das-britische-lebensmittelumfeld-untergraebt-aktiv-die-bemuehungen-der-menschen-abzunehmen-und-ihr-gewicht-zu-halten.html
For National Men’s Health Month, B & W Quality Growers Recommends Adding Watercress to Men’s Diets
Watercress is a superfood and the only food to score perfect on the ANDI and CDC indexes, mehr …
xn--gtsel-kva.de/content/67355/for-national-mens-health-month-b-und-w-quality-growers-recommends-adding-watercress-to-mens-diets.html
Body Mass Index führt ab 40 Jahren in die Irre
Forscher plädieren auf European Congress on Obesity bei Älteren für eine Korrektur nach unten, mehr …
xn--gtsel-kva.de/content/88603/body-mass-index-fuehrt-ab-40-jahren-in-die-irre.html
Parents: Use these six tips to give your child a healthy relationship with their screens
Children with higher screen times are more likely to suffer from health issues like obesity, anxiety and poor emotional development, mehr …
xn--gtsel-kva.de/content/96445/parents-use-these-six-tips-to-give-your-child-a-healthy-relationship-with-their-screens.html
Novo Nordisk A/S, Share repurchase programme
On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …
xn--gtsel-kva.de/content/34308/novo-nordisk-a-s-share-repurchase-programme.html
Enterin and Their Collaborators at NIH Announce That Alpha-Synuclein, the Culprit in Parkinson's Disease, is Core and Central to Normal Immune Function
Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, announces the publication of a paper entitled “Alpha-synuclein, the culprit in Parkinson's Disease, is required for normal immune function.”, mehr …
xn--gtsel-kva.de/content/34405/enterin-and-their-collaborators-at-nih-announce-that-alpha-synuclein-the-culprit-in-parkinson-und-apos-s-disease-is-core-and-central-to-normal-immune-function.html
Novo Nordisk A/S, Share repurchase programme
This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021, mehr …
xn--gtsel-kva.de/content/34754/novo-nordisk-a-s-share-repurchase-programme.html
Enterin to Announce Top-Line Results From the Phase 2b Study for Parkinson’s Disease
Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, today announced that it will host a webinar to present top-line results from the Phase 2b (KARMET) study in patients with Parkinson’s disease on Thursday, Jan. 27 at 2:30 pm EST, mehr …
xn--gtsel-kva.de/content/35483/enterin-to-announce-top-line-results-from-the-phase-2b-study-for-parkinsons-disease.html
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse, mehr …
xn--gtsel-kva.de/content/36257/novo-nordisk-a-s-trading-in-novo-nordisk-shares-by-board-members-executives-and-associated-persons.html
Novo Nordisk – major shareholder announcement
Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 February 2022 holds B shares equal to 5.05% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …
xn--gtsel-kva.de/content/36829/novo-nordisk-major-shareholder-announcement.html
Novo Nordisk A/S: Share repurchase programme
On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …
xn--gtsel-kva.de/content/37458/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk expands research collaboration in novel delivery technologies for biologic medicines
Novo Nordisk today announced the expansion of its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH), mehr …
xn--gtsel-kva.de/content/38647/novo-nordisk-expands-research-collaboration-in-novel-delivery-technologies-for-biologic-medicines.html
Novo Nordisk – major shareholder announcement
Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 March 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …
xn--gtsel-kva.de/content/39024/novo-nordisk-major-shareholder-announcement.html
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending an extension of the Novo Seven (eptacog alfa) label to include treatment of women suffering from severe haemorrhage after giving birth, when medications used to induce uterine contractions and reduce bleeding (uterotonics) are insufficient to stop the bleeding, mehr …
xn--gtsel-kva.de/content/41695/heavy-bleeding-after-giving-birth-is-globally-a-leading-cause-of-death-in-new-mothers.html
Novo Nordisk A/S, Share Repurchase Programme
On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …
xn--gtsel-kva.de/content/43106/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk achieves primary objectives of Onwards 1 and 6 trials
Novo Nordisk today announced headline results from the main phases of Onwards 1 (52 weeks) and Onwards 6 (26 weeks) phase 3a trials with once-weekly insulin icodec, mehr …
xn--gtsel-kva.de/content/44467/novo-nordisk-achieves-primary-objectives-of-onwards-1-and-6-trials.html
Novo Nordisk—major shareholder announcement
Novo Nordisk today announced that the company has been notified by Black Rock, Inc. (Blackrock) that Blackrock as of 31 May 2022 holds B shares equal to below 5 percent of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …
xn--gtsel-kva.de/content/44672/novo-nordisk-major-shareholder-announcement.html
The Worst Habits for Your Dental Health
Credello: Having a healthy smile is more critical than you think. Not only is good dental hygiene crucial for your overall health, but fixing easily avoidable dental issues can cost you thousands of dollars. So before you start looking into dental financing options, try to save yourself a financial hassle by changing any of these bad habits that cause your dental health harm instead, mehr …
xn--gtsel-kva.de/content/50001/the-worst-habits-for-your-dental-health.html
Austin Film Festival 2022 Reveals Second Wave Of Screenings Set For 29th Line-Up
Additional films include Jonathan Dekel’s Checkout and the world premiere of local Austin filmmaker Riley Cusick’s The Wild Man, mehr …
xn--gtsel-kva.de/content/50307/austin-film-festival-2022-reveals-second-wave-of-screenings-set-for-29th-line-up.html
Once-weekly insulin icodec demonstrates superior reduction in HbA1c
Mehr …
p style="line-height:150%;">xn--gtsel-kva.de/content/51554/once-weekly-insulin-icodec-demonstrates-superior-reduction-in-hba1c.html
Novo Nordisk A/S, Share repurchase programme
The execution of Novo Nordisk A/S’ overall share repurchase programme for 2022 of DKK 24 billion continues, mehr …
xn--gtsel-kva.de/content/53353/novo-nordisk-a-s-share-repurchase-programme.html
Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark
Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities, mehr …
xn--gtsel-kva.de/content/54158/novo-nordisk-invests-dkk-5-4-bn-danish-kroner-in-expansion-of-clinical-manufacturing-facilities-in-bagsv-aelig-rd-denmark.html
Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001—a cell therapy designed to restore heart function in people with advanced heart failure
HS 001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs), mehr …
xn--gtsel-kva.de/content/58964/heartseed-and-novo-nordisk-announce-first-patient-dosed-in-clinical-study-with-hs-001-a-cell-therapy-designed-to-restore-heart-function-in-people-with-advanced-heart-failure.html
